Additionally, combination therapies targeting both the ERK1/2 and PI3K pathways have emerged as a promising strategy to overcome resistance and enhance antitumor efficacy in cancers with pathway co-activation or compensatory signaling. The gene discussed is PIK3CD; the disease is cancer.